MK-8617 is a novel potent, selective, orally bioavailable pan-inhibitor of hypoxia-inducible factor prolyl hydroxylase 1−3 (HIF PHD1−3), which inhibits PHD1, 2, 3 with IC50 values of 1.0, 1.0 and 14 nM, respectively.

IOX2 is a novel and potent inhibitor of hypoxia-inducible factor (HIF-1α) prolyl hydroxylase-2 (PHD2) with considerable medical uses.

BAY 87-2243 (BAY-87-2243) is a selective hypoxia-inducible factor-1 (HIF-1) inhibitor with potential anticancer activity.

FG-2216 (YM311; IOX3; YM311) is a novel, potent, and orally bioactive inhibitor of hypoxia-inducible factor-1α (HIF) prolyl 4-hydroxylase (PHD) with the potential to treat anemia.

Roxadustat (FG4592, ASP1517) is a novel, potent and orally bioavailable inhibitor of HIF-PH (hypoxia-inducible factor prolyl hydroxylase) with the potential to treat anemia associated with chronic kidney disease (CKD). HIF-PH is an enzyme that can up-regulate the expression of endogenous human erythropoietin (Epo).

PX-478 2HCl (PX-478 dihydrochloride) is a novel, potent and orally bioactive inhibitor of HIF-1α (hypoxia-inducible factor-1α) with potential antitumor activity.

KC7F2 is a novel and potent HIF-1 (hypoxia inducible factor-1) pathway inhibitor with potential anticancer activity.

OX4 is a potent inhibitor of PHD2 (IC50 = 1.6 nM). IOX4 induces HIFα in cells and in wildtype mice with marked induction in the brain tissue, revealing that it is useful for studies aimed at validating the upregulation of HIF for treatment of cerebral diseases including stroke.

TP0463518 is a novel and potent hypoxia-inducible factor prolyl hydroxylases (PHDs) inhibitor.

IDF-11774 (IDF11774) is a novel, potent, and orally bioavailable HIF-1α (hypoxia-inducible factor 1α) inhibitor with anticancer activity. It inhibits HIF-1α with an IC50 of 3.65 μM. HIF-1 is associated with poor prognoses and therapeutic resistance in cancer patients. IDF-11774 inhibited the accumulation of HIF-1α in vitro and in vivo in colorectal carcinoma HCT116 cells under hypoxic […]